Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.

Pilot Study to Assess the Difference in Glycemic Profiles Between Vildagliptin and Glimepiride Using Continuous Glucose Monitoring Device

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01262586

Enrollment

Registered

2010-12-17

Start date

2010-11-30

Completion date

2011-03-31

Last updated

2016-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II Diabetes Mellitus

Keywords

Type II Diabetes Mellitus, Vildagliptin, Glimepiride, Continuous glucose monitoring

Brief summary

This study will use Continuous Glucose Monitoring to assess differences in glycemic profiles between vildagliptin and glimepiride.

Interventions

DRUGVildagliptin

DRUGGlimepiride

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Type 2 diabetes patients on stable metformin * 18-70 years old * Willing to perform at least 4 capillary blood glucose tests per day

Exclusion criteria

* Type 2 diabetes patients on any other antidiabetic treatment * Patients listed in other trials * Patients with significant diabetic organ disease or complications. Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Change in Glycemic profiles between vildagliptin and glimepiride	Baseline and treatment Day 5, 24hr continuous glucose measurements

Secondary

Measure	Time frame
Glucose Fluctuation before and during treatment	Baseline and treatment Day 5, 24hr continuous measurements

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026